Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  anti-thymocyte globulin
Find trials that include:  Any drugs shown
Results 1-25 of 43 for your search:
Start Over
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
Phase: Phase II, Phase I
Type: Treatment
Age: 17 to 70
Trial IDs: 2067.00, NCI-2011-01352, FHCRC-2067.00, 6364, NCT00622895
Donor Cytokine-Induced Killer Cells in Treating Patients with Myelodysplasia or Myeloproliferative Disorders Previously Treated with Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 50 and over
Trial IDs: BMT217, NCI-2011-01493, SU-04202010-5724, NCT01392989
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients with High Risk Malignancies
Phase: Phase II
Type: Treatment
Age: Under 60
Trial IDs: 2008-0363, NCI-2012-01630, NCT00857389
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 201101864, NCI-2011-00728, 09-0042, NCT00882895
Busulfan and Clofarabine Followed by Donor Stem Cell Transplant in Treating Patients with Acute Leukemia or Lymphoma in Remission or Relapse
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0209, NCI-2012-01270, NCI-2009-01649, NCT00990249
Scleroderma Treatment with Autologous Transplant (STAT) Study
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 69
Trial IDs: 2533.00, NCI-2011-01190, NCT01413100
Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: 0 to 19
Trial IDs: 12-053, NCI-2012-00822, NCT01598025
Ibritumomab Tiuxetan before Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 to 75
Trial IDs: UCDCC#233, NCI-2012-02753, NCT01811368
Donor Stem Cell Transplant in Treating Patients with GATA2 Mutations
Phase: Phase II
Type: Treatment
Age: 6 to 70
Trial IDs: 13-C-0132, NCI-2013-01561, 130132, P131226, NCT01861106
Start Over